Search results for "alas"

showing 10 items of 929 documents

Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia int…

2001

Fifteen beta-thalassemia intermedia patients, not requiring chronic transfusional therapy, were monitored in order to check their antioxidant status, and the lipid oxidation products in plasma, LDL, and erythrocytes before and during a 9-month oral treatment with 600 mg/day vitamin E. The low level of vitamin E, and high level of malondialdehyde in plasma clearly tended to normalize after three months (P < .001), and were quite similar to control after six months. The abnormally low level of vitamin E in LDL and the four times higher than control basal level of conjugated dienes (LDL-CD), were not modified after three months of treatment. Significant changes of LDL-VE (P < .05) and of the b…

AdultMaleVitaminmedicine.medical_specialtyErythrocytesAntioxidantAdolescentmedicine.medical_treatmentAdministration OralHematocritBiochemistryAntioxidantsLipid peroxidationchemistry.chemical_compoundLipid oxidationReference ValuesInternal medicinemedicineHumansVitamin EChildVitamin Amedicine.diagnostic_testVitamin EOsmolar Concentrationbeta-ThalassemiaGeneral MedicineMiddle Agedbeta CaroteneMalondialdehydeLipidsLipoproteins LDLOxidative StressEndocrinologychemistryCase-Control StudiesFemaleHemoglobinFree Radical Research
researchProduct

Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia

2006

Adult thalassemic patients have reduced bone mass due to disturbances in several different mechanisms affecting bone turnover. To determine if vitamin D deficiency contributes to the low bone mass of adult thalassemic subjects, we studied serum 25-OH-vitamin D levels in 90 patients (age ranging between 21 and 48 years) affected with thalassemia major (TM) and 35 (age 21-56 years) with thalassemia intermedia (TI). TM patients had been receiving regular transfusions from the age of 2 years and had increased serum ferritin, glutamic oxalacetic transaminase, glutamic piruvic transaminase as well as low bone density (L1-L4 Z score -2.07 +/- 0.2). TI patients did not receive transfusions, but the…

AdultMaleVitaminmedicine.medical_specialtyHistologyBone densityPhysiologyEndocrinology Diabetes and MetabolismThalassemiavitamin D deficiencyTransaminaseBone remodelingchemistry.chemical_compoundBone DensityInternal medicineVitamin D and neurologyHumansMedicineVitamin DThalassemia majorbusiness.industryMiddle Agedmedicine.diseaseUrinary calciumEndocrinologychemistryParathyroid HormoneThalassemiaFemalebusinessBone
researchProduct

Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterole…

2010

Familial hypercholesterolemia (FH) is a clinical condition with high risk for developing atherosclerosis. Increased oxidative stress (OS) and FH have been related to atherosclerosis, but no data are available on levels of OS and antioxidant enzyme activity in circulating mononuclear cells (CMCs) from FH patients. Circulating mononuclear cells are important mediators in atherosclerosis development, and chronically increased blood OS present in FH can induce modification in CMC activity. The objective of the study was to analyze the OS levels in CMCs from FH patients and controls. We have selected 30 nonrelated FH index patients and 30 normoglycemic and normocholesterolemic controls matched b…

AdultMaleXanthine Oxidasemedicine.medical_specialtyAntioxidantEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFamilial hypercholesterolemiamedicine.disease_causeAntioxidantsHyperlipoproteinemia Type IISuperoxide dismutasechemistry.chemical_compoundEndocrinologyMalondialdehydeInternal medicinemedicineHumansXanthine oxidasechemistry.chemical_classificationGlutathione PeroxidaseGlutathione DisulfidebiologySuperoxide DismutaseGlutathione peroxidaseGlutathioneMiddle AgedAtherosclerosisCatalasemedicine.diseaseGlutathioneOxidative StressEndocrinologychemistryCatalaseLeukocytes Mononuclearbiology.proteinFemaleOxidation-ReductionOxidative stressMetabolism
researchProduct

Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia

2013

Background and Objective Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies like sickle cell disease (SCD) and β-thalassemia. Hydroxyurea (HU) can stimulate HbF production in these diseases but the response is highly variable indicating the utility of developing an in vitro test to predict the patient's response to HU. We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU. Patients and Methods We exposed primary erythroid cultures from peripheral blood mononuclear cells from 30 pat…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesCellPrimary Cell CultureGene ExpressionAnemia Sickle CellBiologyPeripheral blood mononuclear cellhydroxyurealiquid erythroid cultureYoung AdultIn vivohemic and lymphatic diseasesFetal hemoglobinmedicineHumansgamma-GlobinsRNA MessengerFetal HemoglobinAgedErythroid Precursor CellsMessenger RNAbeta-ThalassemiaBeta thalassemiaHematologyGeneral MedicineMiddle Agedmedicine.diseaseb-thalassemiaMolecular biologyReal-time polymerase chain reactionmedicine.anatomical_structureTreatment OutcomeCell cultureFemalesickle cell disease
researchProduct

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).

2019

Fabry's disease (FD) is an X-linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme alpha-galactosidase A (alpha-Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). Patients with amenable mutations can be treated with migalastat, a recently approved oral pharmacologic chaperone to increase endogenous alpha-Gal A activity. We assessed safety along with cardiovascular, renal, and patient-reported outcomes and disease biomarkers in a prospective observational multicenter study after 12 months of migalastat treatment under real-world conditions. Fifty-nine (28 females) patients (34 (57.6%) pretreated with enzyme replacement therapy) w…

AdultMalemedicine.medical_specialty1-DeoxynojirimycinTime FactorsGlobotriaosylceramideRenal function030226 pharmacology & pharmacyGastroenterologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMigalastatGermanymedicineClinical endpointHumansPharmacology (medical)Genetic Predisposition to DiseaseProspective StudiesPharmacologySphingolipidsVentricular Remodelingbusiness.industryEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry's diseaseFabry diseaseBlood pressureTreatment Outcomechemistry030220 oncology & carcinogenesisalpha-GalactosidaseMutationFabry DiseaseFemaleGlycolipidsbusinessBiomarkersGlomerular Filtration RateClinical pharmacology and therapeutics
researchProduct

Pseudoachalasia: a case series and analysis of the literature.

2005

Pseudoachalasia frequently cannot be distinguished from idiopathic achalasia by manometry, radiologic examination or endoscopy. Mechanisms proposed to explain the clinical features of pseudoachalasia include a circumferential mechanical obstruction of the distal esophagus or a malignant infiltration of inhibitory neurons within the myenteric plexus.Between January 1980 and December 2002, the clinical features of 5 patients with pseudoachalasia and 174 patients with primary achalasia, diagnosed in a single center, were compared. A literature analysis of the etiology of pseudoachalasia for the time period 1968 to December 2002 was performed. The search concentrated on the databases and online…

AdultMalemedicine.medical_specialtyAchalasiaFundoplicationCochrane LibrarySingle CenterNeoplasmsmedicineHumansEsophagusDistal esophagusmedicine.diagnostic_testbusiness.industryRadiologic examinationGastroenterologyMiddle Agedmedicine.diseaseEndoscopySurgeryEsophageal Achalasiamedicine.anatomical_structureEtiologyFemaleRadiologybusinessScandinavian journal of gastroenterology
researchProduct

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large mu…

2011

In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statisticall…

AdultMalemedicine.medical_specialtyAdolescentPyridonesThalassemiaClinical BiochemistryDeferoxamineIron Chelating AgentsGastroenterologyDrug Administration Schedulelaw.inventionchemistry.chemical_compoundYoung AdultRandomized controlled triallawInternal medicineMedicineHumansDeferiproneAdverse effectGenetics (clinical)Survival analysisbusiness.industryBiochemistry (medical)Serum ferritin levelbeta-ThalassemiaHematologyIron chelation therapymedicine.diseaseChelation TherapyDeferoxamineTreatment OutcomechemistryDrug Therapy CombinationFemalebusinessDeferiproneThalassemia Iron overload Iron chelation therapy Deferiprone (L1) Deferroxamine (DFO)medicine.drugFollow-Up StudiesHemoglobin
researchProduct

A complication risk score to evaluate clinical severity of thalassaemia syndromes

2020

The thalassaemia syndromes (TS) show different phenotype severity. Developing a reliable, practical and global tool to determine disease severity and tailor treatment would be of great value. Overall, 7910 patients were analysed with the aim of constructing a complication risk score (CoRS) to evaluate the probability of developing one or more complications. Nine independent variables were included in the investigation as predictors. Logistic regression models were used for Group A [transfusion-dependent thalassaemia (TDT)], Group B [transfused non-TDT (NTDT)] and Group C (non-transfused NTDT). Statistically significant predictors included age (years), haemoglobin levels, hepatic transaminas…

AdultMalemedicine.medical_specialtyAdolescentcomplicationsthalassaemiacomplicationrisk scoreLogistic regressionSeverity of Illness IndexGroup AGroup BHemoglobinsYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansprognostic modelBlood TransfusionClinical severityHemoglobinFramingham Risk ScoreEjection fractionReceiver operating characteristicbusiness.industryHematologyMiddle AgedPrognosisChelation TherapyThalassemia ...ROC Curve030220 oncology & carcinogenesisThalassemiaFemalecomplications; prognostic model; risk score; thalassaemiaComplicationbusiness030215 immunologyBritish Journal of Haematology
researchProduct

Antenatal Steroids and Antioxidant Enzyme Activity in Preterm Infants: Influence of Gender and Timing

2009

Antenatal steroids have improved the survival of preterm infants; however, the mechanism of action is not fully understood. We aimed to establish an association between antenatal steroids and antioxidant activity and postnatal oxidative stress. In a prospective cohort study, extremely preterm neonates receiving antenatal steroids (CORT) or not (NOCORT) were enrolled. An association between antenatal steroids and activities of antioxidant enzymes and glutathione cycle enzymes in cord blood was found. In addition, reduced oxidative stress (GSH/GSSG ratio, CORT vs. NOCORT, 35.68 + or - 12.20 vs. 28.38 + or - 9.92; p < 0.01) and, decreased oxidation of proteins (ortho-tyrosine/phenylalanine rat…

AdultMalemedicine.medical_specialtyAntioxidantAdolescentPhysiologymedicine.medical_treatmentClinical BiochemistryBiologymedicine.disease_causeBiochemistryAntioxidantsYoung Adultchemistry.chemical_compoundSex FactorsAdrenal Cortex HormonesPregnancyInternal medicinemedicineHumansProspective StudiesProspective cohort studyMolecular BiologyGeneral Environmental SciencePregnancySuperoxide DismutaseInfant NewbornRetinopathy of prematurityCell BiologyGlutathioneCatalasemedicine.diseaseOxidative StressEndocrinologyBronchopulmonary dysplasiachemistryCord bloodGeneral Earth and Planetary SciencesFemaleInfant PrematureOxidative stressAntioxidants &amp; Redox Signaling
researchProduct

Evaluation of esophagogastric junction relaxation by 4-second Integrated Relaxation Pressure in achalasia using High Resolution Manometry with water-…

2014

Background Relaxation of the esophagogastric junction (EGJ) is now evaluated calculating 4-second integrated relaxation pressure (4-s IRP) by high resolution manometry (HREPT). Solid-state catheters have been used to define abnormal values. Our aim was to evaluate 4-s IRP in esophageal achalasia using HREPT with perfused catheters. Methods From June 2009 to June 2013, 936 HREPT studies have been performed in our unit. Of these, 194 patients having treated achalasia were excluded. Control group was constituted by 695 patients without achalasia, and 47 patients with untreated achalasia constituted the study group. HREPT was performed with water-perfused catheters. To establish the cut-off val…

AdultMalemedicine.medical_specialtyCathetersAdolescentManometryPhysiologyMuscle RelaxationAchalasiaGastroenterologyYoung AdultReference ValuesInternal medicinePressuremedicineotorhinolaryngologic diseasesHumanssclerodermaEsophagogastric junctionHigh resolution manometryAgedAged 80 and overReceiver operating characteristicEndocrine and Autonomic Systemsbusiness.industryhigh resolution manometryGastroenterologyArea under the curveWaterMuscle SmoothMiddle Agedlower esophageal sphincter relaxationmedicine.diseaseEsophageal Achalasiaachalasiaesophageal manometryROC CurveArea Under Curveesophagogastric junction relaxationFemaleEsophagogastric JunctionNuclear medicinebusiness
researchProduct